APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hepatic Encephalopathy Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Hepatic Encephalopathy Drugs Industry Growth and Trends Forecast to 2032

20 December 2025100 pages

Choose your research edition.

Industry ResearchHepatic Encephalopathy Drugs Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatic Encephalopathy Drugs Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Hepatic Encephalopathy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatic Encephalopathy Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatic Encephalopathy Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Hepatic Encephalopathy Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Hepatic Encephalopathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Hepatic Encephalopathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hepatic Encephalopathy Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hepatic Encephalopathy Drugs include Umecrine Cognition, Norgine, Mallinckrodt, Lupin, Kannalife Sciences, Kaleido Biosciences, Ferring Pharmaceuticals, Cosmo Pharmaceuticals and Bausch Health, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Hepatic Encephalopathy Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Hepatic Encephalopathy Drugs market size, estimates, and forecasts are presented in terms of sales volume (tons) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Hepatic Encephalopathy Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Hepatic Encephalopathy Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Hepatic Encephalopathy Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Hepatic Encephalopathy Drugs Market by Company

Umecrine Cognition

Norgine

Mallinckrodt

Lupin

Kannalife Sciences

Kaleido Biosciences

Ferring Pharmaceuticals

Cosmo Pharmaceuticals

Bausch Health

ASKA Pharmaceutical

Hepatic Encephalopathy Drugs Segment by Type

Injection

Oral

Hepatic Encephalopathy Drugs Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Hepatic Encephalopathy Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatic Encephalopathy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatic Encephalopathy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatic Encephalopathy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hepatic Encephalopathy Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Hepatic Encephalopathy Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Injection Table 2. Major Company of Oral Table 3. Global Hepatic Encephalopathy Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Global Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (tons) Table 5. Global Hepatic Encephalopathy Drugs Sales Market Share in Volume by Type (2021-2026) Table 6. Global Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (US$ Million) Table 7. Global Hepatic Encephalopathy Drugs Sales Market Share in Value by Type (2021-2026) Table 8. Global Hepatic Encephalopathy Drugs Price by Type (2021-2026) & (US$/kg) Table 9. Global Hepatic Encephalopathy Drugs Sales by Type (2027-2032) & (tons) Table 10. Global Hepatic Encephalopathy Drugs Sales Market Share in Volume by Type (2027-2032) Table 11. Global Hepatic Encephalopathy Drugs Sales by Type (2027-2032) & (US$ Million) Table 12. Global Hepatic Encephalopathy Drugs Sales Market Share in Value by Type (2027-2032) Table 13. Global Hepatic Encephalopathy Drugs Price by Type (2027-2032) & (US$/kg) Table 14. North America Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (tons) Table 15. North America Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (US$ Million) Table 16. Europe Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (tons) Table 17. Europe Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (US$ Million) Table 18. Asia-Pacific Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (tons) Table 19. Asia-Pacific Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (US$ Million) Table 20. Latin America Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (tons) Table 21. Latin America Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (US$ Million) Table 22. Middle East and Africa Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (tons) Table 23. Middle East and Africa Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (US$ Million) Table 24. Hepatic Encephalopathy Drugs Industry Trends Table 25. Hepatic Encephalopathy Drugs Industry Drivers Table 26. Hepatic Encephalopathy Drugs Industry Opportunities and Challenges Table 27. Hepatic Encephalopathy Drugs Industry Restraints Table 28. Global Hepatic Encephalopathy Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 29. Global Hepatic Encephalopathy Drugs Revenue Market Share by Company (2021-2026) Table 30. Global Hepatic Encephalopathy Drugs Sales by Company (2021-2026) & (tons) Table 31. Global Hepatic Encephalopathy Drugs Sales Share by Company (2021-2026) Table 32. Global Hepatic Encephalopathy Drugs Market Price by Company (2021-2026) & (US$/kg) Table 33. Global Hepatic Encephalopathy Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 34. Global Hepatic Encephalopathy Drugs Major Company Production Sites and Headquarters Table 35. Global Hepatic Encephalopathy Drugs Company, Product Type & Application Table 36. Global Hepatic Encephalopathy Drugs Company Establishment Date Table 37. Global Company Market Concentration Ratio (CR5 and HHI) Table 38. Global Hepatic Encephalopathy Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 39. Global Hepatic Encephalopathy Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 40. Global Hepatic Encephalopathy Drugs Sales by Region (2021-2026) & (tons) Table 41. Global Hepatic Encephalopathy Drugs Sales Market Share in Volume by Region (2021-2026) Table 42. Global Hepatic Encephalopathy Drugs Sales by Region (2021-2026) & (US$ Million) Table 43. Global Hepatic Encephalopathy Drugs Sales Market Share in Value by Region (2021-2026) Table 44. Global Hepatic Encephalopathy Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 45. Global Hepatic Encephalopathy Drugs Sales by Region (2027-2032) & (tons) Table 46. Global Hepatic Encephalopathy Drugs Sales Market Share in Volume by Region (2027-2032) Table 47. Global Hepatic Encephalopathy Drugs Sales by Region (2027-2032) & (US$ Million) Table 48. Global Hepatic Encephalopathy Drugs Sales Market Share in Value by Region (2027-2032) Table 49. Global Hepatic Encephalopathy Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2027-2032) Table 50. Global Hepatic Encephalopathy Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 51. Global Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (tons) Table 52. Global Hepatic Encephalopathy Drugs Sales Market Share in Volume by Application (2021-2026) Table 53. Global Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (US$ Million) Table 54. Global Hepatic Encephalopathy Drugs Sales Market Share in Value by Application (2021-2026) Table 55. Global Hepatic Encephalopathy Drugs Price by Application (2021-2026) & (US$/kg) Table 56. Global Hepatic Encephalopathy Drugs Sales by Application (2027-2032) & (tons) Table 57. Global Hepatic Encephalopathy Drugs Sales Market Share in Volume by Application (2027-2032) Table 58. Global Hepatic Encephalopathy Drugs Sales by Application (2027-2032) & (US$ Million) Table 59. Global Hepatic Encephalopathy Drugs Sales Market Share in Value by Application (2027-2032) Table 60. Global Hepatic Encephalopathy Drugs Price by Application (2027-2032) & (US$/kg) Table 61. North America Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (tons) Table 62. North America Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (US$ Million) Table 63. Europe Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (tons) Table 64. Europe Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (US$ Million) Table 65. Asia-Pacific Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (tons) Table 66. Asia-Pacific Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (US$ Million) Table 67. Latin America Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (tons) Table 68. Latin America Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (US$ Million) Table 69. Middle East and Africa Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (tons) Table 70. Middle East and Africa Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (US$ Million) Table 71. Umecrine Cognition Company Information Table 72. Umecrine Cognition Business Overview Table 73. Umecrine Cognition Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 74. Umecrine Cognition Hepatic Encephalopathy Drugs Product Portfolio Table 75. Umecrine Cognition Recent Development Table 76. Norgine Company Information Table 77. Norgine Business Overview Table 78. Norgine Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 79. Norgine Hepatic Encephalopathy Drugs Product Portfolio Table 80. Norgine Recent Development Table 81. Mallinckrodt Company Information Table 82. Mallinckrodt Business Overview Table 83. Mallinckrodt Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 84. Mallinckrodt Hepatic Encephalopathy Drugs Product Portfolio Table 85. Mallinckrodt Recent Development Table 86. Lupin Company Information Table 87. Lupin Business Overview Table 88. Lupin Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 89. Lupin Hepatic Encephalopathy Drugs Product Portfolio Table 90. Lupin Recent Development Table 91. Kannalife Sciences Company Information Table 92. Kannalife Sciences Business Overview Table 93. Kannalife Sciences Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 94. Kannalife Sciences Hepatic Encephalopathy Drugs Product Portfolio Table 95. Kannalife Sciences Recent Development Table 96. Kaleido Biosciences Company Information Table 97. Kaleido Biosciences Business Overview Table 98. Kaleido Biosciences Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 99. Kaleido Biosciences Hepatic Encephalopathy Drugs Product Portfolio Table 100. Kaleido Biosciences Recent Development Table 101. Ferring Pharmaceuticals Company Information Table 102. Ferring Pharmaceuticals Business Overview Table 103. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 104. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolio Table 105. Ferring Pharmaceuticals Recent Development Table 106. Cosmo Pharmaceuticals Company Information Table 107. Cosmo Pharmaceuticals Business Overview Table 108. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 109. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolio Table 110. Cosmo Pharmaceuticals Recent Development Table 111. Bausch Health Company Information Table 112. Bausch Health Business Overview Table 113. Bausch Health Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 114. Bausch Health Hepatic Encephalopathy Drugs Product Portfolio Table 115. Bausch Health Recent Development Table 116. ASKA Pharmaceutical Company Information Table 117. ASKA Pharmaceutical Business Overview Table 118. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 119. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Product Portfolio Table 120. ASKA Pharmaceutical Recent Development Table 121. North America Hepatic Encephalopathy Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 122. North America Hepatic Encephalopathy Drugs Sales by Country (2021-2026) & (tons) Table 123. North America Hepatic Encephalopathy Drugs Sales Market Share by Country (2021-2026) Table 124. North America Hepatic Encephalopathy Drugs Sales Forecast by Country (2027-2032) & (tons) Table 125. North America Hepatic Encephalopathy Drugs Sales Market Share Forecast by Country (2027-2032) Table 126. North America Hepatic Encephalopathy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 127. North America Hepatic Encephalopathy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 128. North America Hepatic Encephalopathy Drugs Market Share by Country (2021-2026) Table 129. North America Hepatic Encephalopathy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 130. North America Hepatic Encephalopathy Drugs Market Share Forecast by Country (2027-2032) Table 131. Europe Hepatic Encephalopathy Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 132. Europe Hepatic Encephalopathy Drugs Sales by Country (2021-2026) & (tons) Table 133. Europe Hepatic Encephalopathy Drugs Sales Market Share by Country (2021-2026) Table 134. Europe Hepatic Encephalopathy Drugs Sales Forecast by Country (2027-2032) & (tons) Table 135. Europe Hepatic Encephalopathy Drugs Sales Market Share Forecast by Country (2027-2032) Table 136. Europe Hepatic Encephalopathy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 137. Europe Hepatic Encephalopathy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 138. Europe Hepatic Encephalopathy Drugs Market Share by Country (2021-2026) Table 139. Europe Hepatic Encephalopathy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 140. Europe Hepatic Encephalopathy Drugs Market Share Forecast by Country (2027-2032) Table 141. Asia-Pacific Hepatic Encephalopathy Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 142. Asia-Pacific Hepatic Encephalopathy Drugs Sales by Country (2021-2026) & (tons) Table 143. Asia-Pacific Hepatic Encephalopathy Drugs Sales Market Share by Country (2021-2026) Table 144. Asia-Pacific Hepatic Encephalopathy Drugs Sales Forecast by Country (2027-2032) & (tons) Table 145. Asia-Pacific Hepatic Encephalopathy Drugs Sales Market Share Forecast by Country (2027-2032) Table 146. Asia-Pacific Hepatic Encephalopathy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 147. Asia-Pacific Hepatic Encephalopathy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 148. Asia-Pacific Hepatic Encephalopathy Drugs Market Share by Country (2021-2026) Table 149. Asia-Pacific Hepatic Encephalopathy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 150. Asia-Pacific Hepatic Encephalopathy Drugs Market Share Forecast by Country (2027-2032) Table 151. Latin America Hepatic Encephalopathy Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 152. Latin America Hepatic Encephalopathy Drugs Sales by Country (2021-2026) & (tons) Table 153. Latin America Hepatic Encephalopathy Drugs Sales Market Share by Country (2021-2026) Table 154. Latin America Hepatic Encephalopathy Drugs Sales Forecast by Country (2027-2032) & (tons) Table 155. Latin America Hepatic Encephalopathy Drugs Sales Market Share Forecast by Country (2027-2032) Table 156. Latin America Hepatic Encephalopathy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 157. Latin America Hepatic Encephalopathy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 158. Latin America Hepatic Encephalopathy Drugs Market Share by Country (2021-2026) Table 159. Latin America Hepatic Encephalopathy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 160. Latin America Hepatic Encephalopathy Drugs Market Share Forecast by Country (2027-2032) Table 161. Middle East and Africa Hepatic Encephalopathy Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 162. Middle East and Africa Hepatic Encephalopathy Drugs Sales by Country (2021-2026) & (tons) Table 163. Middle East and Africa Hepatic Encephalopathy Drugs Sales Market Share by Country (2021-2026) Table 164. Middle East and Africa Hepatic Encephalopathy Drugs Sales Forecast by Country (2027-2032) & (tons) Table 165. Middle East and Africa Hepatic Encephalopathy Drugs Sales Market Share Forecast by Country (2027-2032) Table 166. Middle East and Africa Hepatic Encephalopathy Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 167. Middle East and Africa Hepatic Encephalopathy Drugs Market Size by Country (2021-2026) & (US$ Million) Table 168. Middle East and Africa Hepatic Encephalopathy Drugs Market Share by Country (2021-2026) Table 169. Middle East and Africa Hepatic Encephalopathy Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 170. Middle East and Africa Hepatic Encephalopathy Drugs Market Share Forecast by Country (2027-2032) Table 171. Key Raw Materials Table 172. Raw Materials Key Suppliers Table 173. Hepatic Encephalopathy Drugs Distributors List Table 174. Hepatic Encephalopathy Drugs Customers List Table 175. Research Programs/Design for This Report Table 176. Authors List of This Report Table 177. Secondary Sources Table 178. Primary Sources List of Figures Figure 1. Hepatic Encephalopathy Drugs Image Figure 2. Global Hepatic Encephalopathy Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatic Encephalopathy Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Hepatic Encephalopathy Drugs Sales (2021-2032) & (tons) Figure 5. Injection Image Figure 6. Global Injection Sales YoY Growth (2021-2032) & (tons) Figure 7. Oral Image Figure 8. Global Oral Sales YoY Growth (2021-2032) & (tons) Figure 9. Global Hepatic Encephalopathy Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 10. Global Hepatic Encephalopathy Drugs Market Share by Type 2025 VS 2032 Figure 11. North America Hepatic Encephalopathy Drugs Sales Market Share in Volume by Type in 2025 Figure 12. North America Hepatic Encephalopathy Drugs Sales Market Share in Value by Type in 2025 Figure 13. Europe Hepatic Encephalopathy Drugs Sales Market Share in Volume by Type in 2025 Figure 14. Europe Hepatic Encephalopathy Drugs Sales Market Share in Value by Type in 2025 Figure 15. Asia-Pacific Hepatic Encephalopathy Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Asia-Pacific Hepatic Encephalopathy Drugs Sales Market Share in Value by Type in 2025 Figure 17. Latin America Hepatic Encephalopathy Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Latin America Hepatic Encephalopathy Drugs Sales Market Share in Value by Type in 2025 Figure 19. Middle East and Africa Hepatic Encephalopathy Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Middle East and Africa Hepatic Encephalopathy Drugs Sales Market Share in Value by Type in 2025 Figure 21. Global Top 5 and 10 Hepatic Encephalopathy Drugs Players Market Share by Revenue in 2025 Figure 22. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 23. Hospital Pharmacies Image Figure 24. Global Hospital Pharmacies Sales YoY Growth (2021-2032) & (tons) Figure 25. Online Pharmacies Image Figure 26. Global Online Pharmacies Sales YoY Growth (2021-2032) & (tons) Figure 27. Retail Pharmacies Image Figure 28. Global Retail Pharmacies Sales YoY Growth (2021-2032) & (tons) Figure 29. Global Hepatic Encephalopathy Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global Hepatic Encephalopathy Drugs Market Share by Application 2025 VS 2032 Figure 31. North America Hepatic Encephalopathy Drugs Sales Market Share in Volume by Application in 2025 Figure 32. North America Hepatic Encephalopathy Drugs Sales Market Share in Value by Application in 2025 Figure 33. Europe Hepatic Encephalopathy Drugs Sales Market Share in Volume by Application in 2025 Figure 34. Europe Hepatic Encephalopathy Drugs Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific Hepatic Encephalopathy Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific Hepatic Encephalopathy Drugs Sales Market Share in Value by Application in 2025 Figure 37. Latin America Hepatic Encephalopathy Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Latin America Hepatic Encephalopathy Drugs Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa Hepatic Encephalopathy Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa Hepatic Encephalopathy Drugs Sales Market Share in Value by Application in 2025 Figure 41. North America Hepatic Encephalopathy Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 42. North America Hepatic Encephalopathy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America Hepatic Encephalopathy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America Hepatic Encephalopathy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe Hepatic Encephalopathy Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 46. Europe Hepatic Encephalopathy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Hepatic Encephalopathy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe Hepatic Encephalopathy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific Hepatic Encephalopathy Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 50. Asia-Pacific Hepatic Encephalopathy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Hepatic Encephalopathy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific Hepatic Encephalopathy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Hepatic Encephalopathy Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 54. Latin America Hepatic Encephalopathy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Hepatic Encephalopathy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America Hepatic Encephalopathy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa Hepatic Encephalopathy Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 58. Middle East and Africa Hepatic Encephalopathy Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Hepatic Encephalopathy Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa Hepatic Encephalopathy Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Hepatic Encephalopathy Drugs Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. Hepatic Encephalopathy Drugs Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Oral
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Umecrine Cognition
  • Norgine
  • Mallinckrodt
  • Lupin
  • Kannalife Sciences
  • Kaleido Biosciences
  • Ferring Pharmaceuticals
  • Cosmo Pharmaceuticals
  • Bausch Health
  • ASKA Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hepatic Encephalopathy Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Hepatic Encephalopathy Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Hepatic Encephalopathy Drugs Market by Type
  6. 1.3.1 Injection
  7. 1.3.2 Oral
  8. 1.4 Global Hepatic Encephalopathy Drugs Market Size by Type
  9. 1.4.1 Global Hepatic Encephalopathy Drugs Market Size Overview by Type (2021-2032)
  10. 1.4.2 Global Hepatic Encephalopathy Drugs Historic Market Size Review by Type (2021-2026)
  11. 1.4.3 Global Hepatic Encephalopathy Drugs Forecasted Market Size by Type (2027-2032)
  12. 1.5 Key Regions Market Size by Type
  13. 1.5.1 North America Hepatic Encephalopathy Drugs Sales Breakdown by Type (2021-2026)
  14. 1.5.2 Europe Hepatic Encephalopathy Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.3 Asia-Pacific Hepatic Encephalopathy Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.4 South America Hepatic Encephalopathy Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.5 Middle East and Africa Hepatic Encephalopathy Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Hepatic Encephalopathy Drugs Industry Trends
  2. 2.2 Hepatic Encephalopathy Drugs Industry Drivers
  3. 2.3 Hepatic Encephalopathy Drugs Industry Opportunities and Challenges
  4. 2.4 Hepatic Encephalopathy Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Hepatic Encephalopathy Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Hepatic Encephalopathy Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Hepatic Encephalopathy Drugs Price (2021-2026)
  4. 3.4 Global Hepatic Encephalopathy Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hepatic Encephalopathy Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Hepatic Encephalopathy Drugs Company, Product Type & Application
  7. 3.7 Global Hepatic Encephalopathy Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hepatic Encephalopathy Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hepatic Encephalopathy Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hepatic Encephalopathy Drugs Tier 1, Tier 2, and Tier 3
4 Hepatic Encephalopathy Drugs Regional Status and Outlook
  1. 4.1 Global Hepatic Encephalopathy Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Hepatic Encephalopathy Drugs Historic Market Size by Region
  3. 4.2.1 Global Hepatic Encephalopathy Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Hepatic Encephalopathy Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Hepatic Encephalopathy Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Hepatic Encephalopathy Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Hepatic Encephalopathy Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Hepatic Encephalopathy Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Hepatic Encephalopathy Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Hepatic Encephalopathy Drugs by Application
  1. 5.1 Hepatic Encephalopathy Drugs Market by Application
  2. 5.1.1 Hospital Pharmacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Retail Pharmacies
  5. 5.2 Global Hepatic Encephalopathy Drugs Market Size by Application
  6. 5.2.1 Global Hepatic Encephalopathy Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Hepatic Encephalopathy Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Hepatic Encephalopathy Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Hepatic Encephalopathy Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Hepatic Encephalopathy Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Hepatic Encephalopathy Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Hepatic Encephalopathy Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Hepatic Encephalopathy Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Umecrine Cognition
  2. 6.1.1 Umecrine Cognition Company Information
  3. 6.1.2 Umecrine Cognition Business Overview
  4. 6.1.3 Umecrine Cognition Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Umecrine Cognition Hepatic Encephalopathy Drugs Product Portfolio
  6. 6.1.5 Umecrine Cognition Recent Developments
  7. 6.2 Norgine
  8. 6.2.1 Norgine Company Information
  9. 6.2.2 Norgine Business Overview
  10. 6.2.3 Norgine Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Norgine Hepatic Encephalopathy Drugs Product Portfolio
  12. 6.2.5 Norgine Recent Developments
  13. 6.3 Mallinckrodt
  14. 6.3.1 Mallinckrodt Company Information
  15. 6.3.2 Mallinckrodt Business Overview
  16. 6.3.3 Mallinckrodt Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Mallinckrodt Hepatic Encephalopathy Drugs Product Portfolio
  18. 6.3.5 Mallinckrodt Recent Developments
  19. 6.4 Lupin
  20. 6.4.1 Lupin Company Information
  21. 6.4.2 Lupin Business Overview
  22. 6.4.3 Lupin Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Lupin Hepatic Encephalopathy Drugs Product Portfolio
  24. 6.4.5 Lupin Recent Developments
  25. 6.5 Kannalife Sciences
  26. 6.5.1 Kannalife Sciences Company Information
  27. 6.5.2 Kannalife Sciences Business Overview
  28. 6.5.3 Kannalife Sciences Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Kannalife Sciences Hepatic Encephalopathy Drugs Product Portfolio
  30. 6.5.5 Kannalife Sciences Recent Developments
  31. 6.6 Kaleido Biosciences
  32. 6.6.1 Kaleido Biosciences Company Information
  33. 6.6.2 Kaleido Biosciences Business Overview
  34. 6.6.3 Kaleido Biosciences Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Kaleido Biosciences Hepatic Encephalopathy Drugs Product Portfolio
  36. 6.6.5 Kaleido Biosciences Recent Developments
  37. 6.7 Ferring Pharmaceuticals
  38. 6.7.1 Ferring Pharmaceuticals Company Information
  39. 6.7.2 Ferring Pharmaceuticals Business Overview
  40. 6.7.3 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolio
  42. 6.7.5 Ferring Pharmaceuticals Recent Developments
  43. 6.8 Cosmo Pharmaceuticals
  44. 6.8.1 Cosmo Pharmaceuticals Company Information
  45. 6.8.2 Cosmo Pharmaceuticals Business Overview
  46. 6.8.3 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolio
  48. 6.8.5 Cosmo Pharmaceuticals Recent Developments
  49. 6.9 Bausch Health
  50. 6.9.1 Bausch Health Company Information
  51. 6.9.2 Bausch Health Business Overview
  52. 6.9.3 Bausch Health Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Bausch Health Hepatic Encephalopathy Drugs Product Portfolio
  54. 6.9.5 Bausch Health Recent Developments
  55. 6.10 ASKA Pharmaceutical
  56. 6.10.1 ASKA Pharmaceutical Company Information
  57. 6.10.2 ASKA Pharmaceutical Business Overview
  58. 6.10.3 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Product Portfolio
  60. 6.10.5 ASKA Pharmaceutical Recent Developments
7 North America by Country
  1. 7.1 North America Hepatic Encephalopathy Drugs Sales by Country
  2. 7.1.1 North America Hepatic Encephalopathy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Hepatic Encephalopathy Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Hepatic Encephalopathy Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Hepatic Encephalopathy Drugs Market Size by Country
  6. 7.2.1 North America Hepatic Encephalopathy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Hepatic Encephalopathy Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Hepatic Encephalopathy Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Hepatic Encephalopathy Drugs Sales by Country
  2. 8.1.1 Europe Hepatic Encephalopathy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Hepatic Encephalopathy Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Hepatic Encephalopathy Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Hepatic Encephalopathy Drugs Market Size by Country
  6. 8.2.1 Europe Hepatic Encephalopathy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Hepatic Encephalopathy Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Hepatic Encephalopathy Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Hepatic Encephalopathy Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Hepatic Encephalopathy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Hepatic Encephalopathy Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Hepatic Encephalopathy Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Hepatic Encephalopathy Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Hepatic Encephalopathy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Hepatic Encephalopathy Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Hepatic Encephalopathy Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Hepatic Encephalopathy Drugs Sales by Country
  2. 10.1.1 South America Hepatic Encephalopathy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Hepatic Encephalopathy Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Hepatic Encephalopathy Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Hepatic Encephalopathy Drugs Market Size by Country
  6. 10.2.1 South America Hepatic Encephalopathy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Hepatic Encephalopathy Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Hepatic Encephalopathy Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Hepatic Encephalopathy Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Hepatic Encephalopathy Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Hepatic Encephalopathy Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Hepatic Encephalopathy Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Hepatic Encephalopathy Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Hepatic Encephalopathy Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Hepatic Encephalopathy Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Hepatic Encephalopathy Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Hepatic Encephalopathy Drugs Value Chain Analysis
  2. 12.1.1 Hepatic Encephalopathy Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Hepatic Encephalopathy Drugs Production Mode & Process
  7. 12.2 Hepatic Encephalopathy Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Hepatic Encephalopathy Drugs Distributors
  10. 12.2.3 Hepatic Encephalopathy Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst